Metadichol Orchestrates T, B, and NK Cell Immunity Through Master Regulator Gene Networks

Background: The 2025 Nobel Prize in Physiology or Medicine recognized the fundamental discovery of regulatory T cells and the FOXP3 gene as critical mediators of peripheral immune tolerance. This landmark workestablished a single-pathway mechanism for immune regulation Metadichol, a nanoemulsion of long-chainalcohols C26-C32, demonstrates pleiotropic immunomodulatory effects through coordinated regulation of masterregulator genes involved in T-cell function, B-cell development, NK cell cytotoxicity, metabolic reprogramming,and tumor suppression. Methods: We analyzed gene expression data from Metadichol-treated peripheral blood mononuclear cells PBMCs and resting fibroblasts across four concentrations 1 pg/mL, 100 pg/mL, 1 ng/mL, 100 ng/mL. A total of 36 master regulator genes were examined, including CD markers, transcription factors, and metabolic regulators. Comprehensive bioinformatic analysis included correlation network mapping, hierarchical clustering, and functional pathway enrichment to identify synergistic and antagonistic gene expression patterns. Results: Metadichol induced dramatic upregulation of key metabolic regulators including PPARγ 24.25-fold, PGC1α 11.08-fold, and tumor suppressor p53 9.61-fold, while coordinately modulating T-cell markers CD4 2.03-fold and CD8 2.15-fold. Correlation analysis revealed three strategic mechanisms: • Synergistic metabolic reprogramming through PPARγ-PGC1α co- activation r=0.991, • Immune balance optimization via antagonistic regulation of effector CDS versus suppressor FOXP3 functions, and • Dfferential cell-type regulation exemplified by the CDS-p53 antagonism r=-0.991. The upregulation of FOXP3 1.87-fold, the master regulator of regulatory T cells Tregs.